ClinicalTrials.gg
CompletedNCT02206425Updated Oct 31, 2023

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

A Phase 1/2 interventional study of Melphalan and Prednisone in Multiple Myeloma, sponsored by Oncotherapeutics. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-31.

Sponsored by Oncotherapeutics · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 140 studies testing melphalan in Multiple Myeloma — 3 open to participants now, 10 under way, 1 of them phase 3. Melphalan · Multiple Myeloma.

Enrollment
64th of 127
45 · median 45
Started
2014
with 6 others
Phase 1/2
25 of 140
none open now
Registered
113th of 140
by date

Among the 140 studies testing melphalan in Multiple Myeloma, this one is the 64th largest by enrollment of the 127 interventional ones that give a count, is one of 7 that started in 2014, is one of 25 in phase 1/2, and was the 113th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

3 of the 140 studies testing melphalan in Multiple Myeloma are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About melphalan

Melphalan: first FDA approval 1964 (ALKERAN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 140 studies testing melphalan in Multiple Myeloma, or all of them as a file.
02

Study summary

The goal of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of ixazomib given as part of a combination therapy to treat subjects with relapsed (subjects whose disease came back) or refractory (subjects whose disease did not respond to past treatment) multiple myeloma. More specifically, the study is focused on subjects who were previously treated with bortezomib (Velcade®) or carfilzomib (Kyprolis®) and showed worsening of their myeloma while receiving either one of these drugs in combination therapy. This study is a Phase I/II. Ixazomib is an investigational drug, which means that ixazomib is currently being tested and is not yet approved by the United States Food and Drug Administration (FDA) for subjects with relapsed or refractory multiple myeloma. Ixazomib is a new study drug that belongs to the same class as bortezomib and carfilzomib; however, unlike bortezomib and carfilzomib, ixazomib is taken by mouth. Current studies investigating ixazomib are demonstrating that it is as safe as bortezomib and effective for the treatment of multiple myeloma both on its own and in combination with other multiple myeloma medications, such as lenalidomide and dexamethasone, or prednisone and melphalan.

Read the detailed description

This is a phase 1/2, intra-patient, multicenter, open-label and non-randomized study to evaluate the efficacy and safety of ixazomib as a replacement for bortezomib or carfilzomib among multiple myeloma (MM) patients who have failed proteasome inhibitor (PI)-containing combination regimens. Patients will receive ixazomib once a week in place of bortezomib or carfilzomib in combination with an alkylating agent (melphalan or cyclophosphamide), anthracycline (pegylated doxorubicin [PLD]), immunomodulatory agent (lenalidomide, pomalidomide), ascorbic acid and/or a glucocorticosteroid (dexamethasone, prednisone or methylprednisolone) administered using the same dose(s) and schedule(s) as the last PI-containing regimen that the patients had received and failed. The total number of different prior bortezomib- or carfilzomib-containing regimens that will be evaluated is 10, reflecting those commonly used in the community as follows:

  • bortezomib + melphalan + prednisone
  • bortezomib + cyclophosphamide + ascorbic acid
  • bortezomib + cyclophosphamide + dexamethasone
  • bortezomib + PLD + dexamethasone
  • bortezomib + dexamethasone
  • carfilzomib + dexamethasone
  • bortezomib + lenalidomide + dexamethasone
  • bortezomib + pomalidomide + dexamethasone
  • carfilzomib + lenalidomide + dexamethasone
  • carfilzomib + pomalidomide + dexamethasone

This study will enroll 60 patients who are refractory to a bortezomib- or carfilzomib-containing combination regimen, as demonstrated by progressive disease (PD) while being treated, or who have relapsed within 8 weeks from the last dose of bortezomib or carfilzomib in their last PI-containing combination regimen.

Ixazomib will replace bortezomib or carfilzomib using the same PI-containing regimen the patients failed.The study will consist of: 1) a screening period; 2) up to eight 28-day treatment cycles; 3) a maintenance period; 4) a final assessment to occur 28 days after the end of the last treatment cycle; and 5) a follow-up period.

Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle to patients enrolled in seven regimens (bortezomib + melphalan + prednisone, bortezomib + dexamethasone, carfilzomib + dexamethasone, bortezomib + lenalidomide + dexamethasone, bortezomib + pomalidomide + dexamethasone, carfilzomib + lenalidomide + dexamethasone, carfilzomib + pomalidomide + dexamethasone). Subjects on those regimens receiving 4 mg of ixazomib from the beginning of the trial will continue to do so for the length of the study, unless they suffer from adverse events requiring dose reductions. For the other three regimens, bortezomib + cyclophosphamide + dexamethasone, bortezomib + cyclophosphamide + ascorbic acid, and bortezomib + PLD + dexamethasone, the MTD for ixazomib is unknown and intra-patient dose escalation will be performed to determine the specific MTD for each of them. For these three regimens, ixazomib will be administered on Days 1, 8 and 15 of a 28-day cycle at a starting dose of 3 mg in Cycle 1, and then intra-patient dose-escalation will proceed to 4 mg in Cycle 2. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • multiple myeloma
  • Relapsed/refractory
  • Ixazomib
  • Proteasome inhibitor
  • Oral
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male or female patients 18 years or older
  2. Patients must have a diagnosis of MM, based on standard criteria as follows:

    • Major criteria:

      1. plasmacytomas on tissue
      2. bone marrow plasmacytosis (greater than 30% plasma cells)
      3. monoclonal immunoglobulin spike on serum electrophoresis IgG greater than 3.5 g/dL or IgA greater than 2.0 g/dL; kappa or lambda light chain excretion greater than 1 g/day on 24 hour urine protein electrophoresis
    • Minor criteria:

      1. bone marrow plasmacytosis (10% to 30% plasma cells)
      2. monoclonal immunoglobulin present but of lesser magnitude than given under major criteria
      3. lytic bone lesions
      4. normal IgM less than 50 mg/dL, IgA less than 100 mg/dL, or IgG less than 600 mg/dL

    Any of the following sets of criteria will confirm the diagnosis of multiple myeloma:

    • any 2 of the major criteria
    • major criterion 1 plus minor criterion 2, 3, or 4
    • major criterion 3 plus minor criterion 1 or 3
    • minor criteria 1, 2, and 3, or 1, 2, and 4
  3. Currently has progressive MM that has previously progressed or is currently progressing while receiving or within 8 weeks of receiving bortezomib or carfilzomib as part of a combination treatment. MM patients that demonstrate disease, as defined below, are both eligible for enrollment provided they fulfill the other eligibility criteria:

    • Patients are refractory to a bortezomib or carfilzomib combination regimen, when they progress while currently receiving a bortezomib or carfilzomib combination treatment, or within 8 weeks of its last dose. Patients are considered relapsed, when they progress between 8 and 12-weeks from their last dose of bortezomib or carfilzomib as part of a bortezomib or carfilzomib combination therapy. Prior treatment with four days or less of a total of 400 mg of prednisone (or an equivalent potency of another ) for MM will not be considered a regimen.
  4. Patients that were on bortezomib-containing regimens must have been administered at least 4 doses of a minimum of 1.0 mg/m2 in no more than 28-days cycles. Subjects must have received at least one cycle meeting this definition and have shown PD to be considered eligible
  5. Patients that were on carfilzomib-containing regimens must have received at least 6 doses of at least 27 mg/m2 in no more than 28 days per cycle. Subjects must have received at least one cycle meeting this definition and have shown PD to be considered eligible
  6. Progressed from one of the specific bortezomib- or carfilzomib-containing regimens as listed on page 51. Although bortezomib- and carfilzomib-containing combination regimens that are otherwise identical except for the PI result in the same ixazomib regimen, they will be enrolled separately so that safety/efficacy can be separately determined, thereby allowing comparisons based on the prior PI that subjects were exposed to as part of the regimen that they failed (carfilzomib vs. bortezomib)
  7. Patient may have received a carfilzomib- or bortezomib-containing regimen at any time and may have received other non-proteasome inhibitor-containing intervening treatments

Key Exclusion Criteria:

  1. Patient has been diagnosed with:

    1. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M protein) and skin changes (POEMS) syndrome.3
    2. Primary amyloidosis
    3. Plasma cell leukemia
    4. Severe hypercalcemia, i.e., serum calcium = 12 mg/dL (3.0 mmol/L) corrected for albumin
  2. Diagnosed or treated for another within 3 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with non-melanomatous skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
  3. Impaired cardiac function or cardiac diseases, including myocardial infarction within 6 months prior to enrollment, (NYHA) Class II or greater heart failure, uncontrolled angina, clinically significant pericardial disease, severe uncontrolled ventricular arrhythmias, echocardiogram or multigated acquisition scan () evidence of left ventricular ejection fraction (LVEF) below institutional normal within 28 days prior to enrollment, electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any abnormality at Screening has to be documented by the investigator as not medically relevant
  4. Patient has peripheral neuropathy grade 3 or higher or Grade 2 with pain on clinical examination during the screening period
  5. Patient has received the following prior therapy:

    1. Chemotherapy within 21 days of enrollment (6 weeks for nitrosoureas)
    2. Corticosteroids (>10 mg/day prednisone or equivalent) within 21 days of enrollment
    3. Immunotherapy or antibody therapy as well as thalidomide, pomalidomide, lenalidomide, arsenic trioxide, carfilzomib, or bortezomib within 21 days before enrollment
  6. Known allergy to any of the study medications, their analogues, or in the various formulations of any agent
  7. Known GI disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    bortezomib + melphalan + prednisone

    Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.

    Drug: Melphalan · Drug: Prednisone

  • Experimental
    bortezomib + dexamethasone

    Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.

    Drug: Dexamethasone

  • Experimental
    carfilzomib + dexamethasone

    Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.

    Drug: Dexamethasone

  • Experimental
    bortezomib + lenalidomide + dexamethasone

    Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.

    Drug: Dexamethasone · Drug: Lenalidomide

  • Experimental
    carfilzomib + lenalidomide + dexamethasone

    Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.

    Drug: Dexamethasone · Drug: Lenalidomide

  • Experimental
    bortezomib + cyclophosphamide + dexamethasone

    MTD determination. Ixazomib will be administered on Days 1, 8 and 15 of a 28-day cycle at a starting dose of 3 mg in Cycle 1, and then intra-patient dose-escalation will proceed to 4 mg in Cycle 2. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.

    Drug: Cyclophosphamide · Drug: Dexamethasone

  • Experimental
    bortezomib + cyclophosphamide + ascorbic acid

    MTD determination. Ixazomib will be administered on Days 1, 8 and 15 of a 28-day cycle at a starting dose of 3 mg in Cycle 1, and then intra-patient dose-escalation will proceed to 4 mg in Cycle 2. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib. Due to a potential drug-drug interaction between ixazomib and ascorbic acid, patients will receive ixazomib in the clinic in the morning and will be instructed to take ascorbic acid in the evening, followed by cyclophosphamide.

    Drug: Cyclophosphamide · Dietary Supplement: Ascorbic acid

  • Experimental
    bortezomib + PLD + dexamethasone

    MTD determination. Ixazomib will be administered on Days 1, 8 and 15 of a 28-day cycle at a starting dose of 3 mg in Cycle 1, and then intra-patient dose-escalation will proceed to 4 mg in Cycle 2. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.

    Drug: Dexamethasone · Drug: PLD

  • Experimental
    bortezomib + pomalidomide + dexamethasone

    Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.

    Drug: Dexamethasone · Drug: Pomalidomide

  • Experimental
    carfilzomib + pomalidomide + dexamethasone

    Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.

    Drug: Dexamethasone · Drug: Pomalidomide

Interventions

  • Melphalan will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).

    Also known as: Phenylalanine mustard, Alkeran

  • Prednisone will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).

    Also known as: Cortan, Deltasone, Orasone, Prednisone Intensol, Sterapred, Sterapred DS

  • Cyclophosphamide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).

    Also known as: Cytoxan, CPM, CTX, CYT

  • Dexamethasone will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).

    Also known as: Decadron, Dexamethasone Intensol, Dexpak Taperpak

  • Dietary supplementAscorbic acid

    Vitamin C will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).

    Also known as: Vitamin C

  • DrugPLD

    Pegylated liposomal doxorubicin will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).

    Also known as: ATI-0918, doxorubicin hydrochloride liposome, doxorubicin hydrochloride liposome injection, liposomal adriamycin, liposomal doxorubicin, liposomal doxorubicin hydrochloride, liposome-encapsulated doxorubicin, pegylated doxorubicin HCl liposome, Pegylated Liposomal Doxorubicin, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, DOXIL, Dox-SL, Evacet, LipoDox

  • Lenalidomide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).

    Also known as: Revlimid

  • Pomalidomide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).

    Also known as: Pomalyst

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD) for selected regimens

    MTD determined via the number of dose-limiting toxicities (DLTs) per cohort for the following ixazomib- containing combinations: bortezomib+ cyclophosphamide + dexamethasone, bortezomib + cyclophosphamide + ascorbic acid, bortezomib + PLD + dexamethasone

    Time frame: Cycles 1-2 for selected regimens (up to 2 months)

  2. Number of subjects with adverse events

    Occurrence of adverse events throughout the study, graded via CTCAE v 4.03 criteria

    Time frame: up to 48 months

  3. Overall response rate (ORR)

    Complete response (CR)+ very good partial response (VGPR) + partial response (PR), defined using IMWG criteria

    Time frame: up to 48 months

  4. Clinical benefit rate (CBR)

    CBR=ORR + minor response (MR)

    Time frame: up to 48 months

Secondary outcomes

  1. Time to Progression

    Time from initiation of therapy to progressive disease

    Time frame: at least over 48 months

  2. Progression-free survival (PFS)

    Time from initiation of therapy to progressive disease or death from any cause, whichever occurs first

    Time frame: at least over 48 months

  3. Time to response (TTR)

    Time from the initiation of therapy to the first evidence of a confirmed response

    Time frame: up to 48 months

  4. Duration of response (DOR)

    Time from the first response (\> PR) to progressive disease

    Time frame: at least over 48 months

  5. Overall survival (OS)

    Time from initiation of therapy to death from any cause or last follow-up visit

    Time frame: at least over 48 months

  6. Peripheral Neuropathy (PN)

    Incidence and severity among patients receiving ixazomib compared to their baseline PN when they entered the trial, defined by CTCAE v4.0.3 and FACT-GOG/NTX questionnaire score.

    Time frame: up to 48 months

07

Study locations

12 sites
  • Comprehensive Blood and Cancer Center
    Bakersfield, California 93309, United States
  • John Muir Health Clinical Research Center
    Concord, California 94520, United States
  • California Cancer Associates for Research & Excellence (cCARE)
    Encinitas, California 92024, United States
  • Robert A. Moss, MD, FACP, Inc
    Fountain Valley, California 92708, United States
  • cCARE Fresno
    Fresno, California 93720, United States
  • Comprehensive Cancer Center at Desert Regional Medical Center
    Palm Springs, California 92262, United States
  • James Berenson, MD, Inc
    West Hollywood, California 90069, United States
  • Cancer Specialists of North Florida
    Fleming Island, Florida 32003, United States
  • Lewis Hall Singletary Oncology Center
    Thomasville, Georgia 31792, United States
  • Oncology Specialists, SC
    Niles, Illinois 60714, United States
  • Hattiesburg Clinic Hematology/Oncology
    Hattiesburg, Mississippi 39401, United States
  • Vista Oncology
    Olympia, Washington 98502, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2014 to primary completion in Jan 2018, 40 months.

Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's 40 months is below that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2014
First posted
Aug 1, 2014
StartActual
Sep 2014
Primary completionActual
Jan 19, 2018
CompletionActual
Mar 6, 2018
Last update
Oct 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02206425
Lead sponsor
Oncotherapeutics
Collaborators
Takeda
Responsible party
Sponsor
First posted
Aug 1, 2014
Start date
Sep 2014
Primary completion
Jan 19, 2018
Completion
Mar 6, 2018
Last update
Oct 31, 2023

Study contacts

James R Berenson, MD
principal investigator · James R. Berenson MD, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Melphalan · Prednisone · Cyclophosphamide · Dexamethasone · Ascorbic Acid · Liposomal doxorubicin · Lenalidomide · Pomalidomide

Start the discussion